Detail akcie Nuvation Bio Rg-A online

Business Summary: Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Nuvation Bio Inc revenues increased from $2.2M to $21M. Net loss decreased 68% to $168M. Revenues reflect Collaboration and license agreements rev increase from $2.2M to $12.1M. Lower net loss reflects Oncology Development activities segment loss decrease of 67% to $179M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.11 to -$0.49.